Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 22, 23 | -0.60 Increased by +34.78% | -0.41 Decreased by -113.03% |
| Nov 21, 22 | -0.47 Increased by +48.91% | -0.17 Decreased by -1.04 K% |
| Aug 16, 22 | -0.45 Increased by +76.80% | -0.06 Decreased by -10.83 K% |
| May 16, 22 | -0.44 Increased by +20.00% | -0.51 Increased by +26.91% |
| Apr 1, 22 | -0.92 Decreased by -19.48% | -0.41 Decreased by -303.39% |
| Mar 31, 22 | -0.92 Decreased by -55.93% | -0.41 Decreased by -303.39% |
| Nov 10, 21 | -1.94 Decreased by -198.46% | -0.51 Decreased by -549.79% |
| Aug 12, 21 | -0.55 Decreased by -17.02% | -0.63 Increased by +20.16% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 0.00 Decreased by N/A% | -9.07 M Decreased by N/A% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 292.00 K Increased by +N/A% | -8.22 M Decreased by N/A% | Decreased by -2.82 K% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -8.11 M Decreased by N/A% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 570.00 K Increased by +N/A% | -10.47 M Decreased by N/A% | Decreased by -1.84 K% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | 0.00 Decreased by N/A% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | 0.00 Decreased by N/A% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 21 | 0.00 Decreased by N/A% | 0.00 Decreased by N/A% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 20 | 0.00 Decreased by N/A% | 0.00 Decreased by N/A% | Decreased by N/A% Decreased by N/A% |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.